Kaisorn L. Chaichana
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Kaisorn L. Chaichana has a total of 244 co-authors. Here are the top co-authors by number of shared publications:
- Alfredo Quiñones-Hinojosa
Department of Neurosurgery, Mayo Clinic College of Medicine and Sciences, Jacksonville, USA
15 shared publications Alfredo Quinones-Hinojosa
Department of Neurological Surgery, Mayo Clinic, Jacksonville, USA
14 shared publicationsLina Marenco-Hillembrand
Department of Neurological Surgery, University of Iowa Hospitals, Iowa City, USA
12 shared publicationsPaola Suarez-Meade
Department of Neurological Surgery, Mayo Clinic, Jacksonville, FL, USA
7 shared publications- Erik H. Middlebrooks
Department of Radiology Mayo Clinic Jacksonville Florida USA
6 shared publications David Mampre
Department of Neurosurgery, Johns Hopkins University, Baltimore, Maryland; and
5 shared publications
Latest Publications
- Open Access
- 15 June 2026
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 28 (9) , 2136-2152
Multi-sampling allows intra-tumoral heterogeneity querying and vulnerability profiling in glioblastoma
Background: Glioblastoma (GBM) remains a devastating cancer with limited treatment options, largely due to its heterogeneity. While supramaximal resection has recently provided survival benefits, therapeutic profiling of different tumor compartments, particularly its infiltrative edge remains largely unexplored. Methods: Here, we leveraged magnetic resonance imaging (MRI)-guided multi-sampling, collecting 2 cores and 2 margins per case, to query GBM heterogeneity. Whole-exome and RNA-seq with drug testing in two patient-derived 3D models were used to reveal similarities and differences in genomic and transcriptomic makeups, cellular compositions, and drug responses across cores and margins. Bioinformatics interrogations further identified response biomarkers. Results: Mutation analysis showed that oncogenes exhibited a higher degree of spatial heterogeneity than tumor suppressor genes, regardless of MRI status. While the mesenchymal transcriptional subtype with extracellular matrix remodeling, stress response, and immune programs were preferentially enriched in enhancing cores, proneural tumors with neurological processes favored non-enhancing margins. Using a 15-drug GBM-targeted panel, ERK (ulixertinib) and PI3K pathway (paxalisib, CC-115) inhibitors showed preferential efficacy in enhancing cores and non-enhancing margins, respectively. The anti-apoptosis, pan-Bcl2 agent navitoclax and the epigenetic drug trotabresib represented the most effective, tumor-wide monotherapies. Importantly, drug combinations generally outperformed single agents across all regions. Conclusions: This work demonstrates the regional heterogeneity of therapeutic vulnerabilities in GBM ex vivo, showing various drugs with tumor-wide or MRI-enhancement informed activity. These findings offer preclinical bases of numerous monotherapies and drug combinations for future clinical trial design.
- 15 June 2026
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 28 (9) , 2136-2152
Open AccessMulti-sampling allows intra-tumoral heterogeneity querying and vulnerability profiling in glioblastoma
Background: Glioblastoma (GBM) remains a devastating cancer with limited treatment options, largely due to its heterogeneity. While supramaximal resection has recently provided survival benefits, therapeutic profiling of different tumor compartments, particularly its infiltrative edge remains largely unexplored. Methods: Here, we leveraged magnetic resonance imaging (MRI)-guided multi-sampling, collecting 2 cores and 2 margins per case, to query GBM heterogeneity. Whole-exome and RNA-seq with drug testing in two patient-derived 3D models were used to reveal similarities and differences in genomic and transcriptomic makeups, cellular compositions, and drug responses across cores and margins. Bioinformatics interrogations further identified response biomarkers. Results: Mutation analysis showed that oncogenes exhibited a higher degree of spatial heterogeneity than tumor suppressor genes, regardless of MRI status. While the mesenchymal transcriptional subtype with extracellular matrix remodeling, stress response, and immune programs were preferentially enriched in enhancing cores, proneural tumors with neurological processes favored non-enhancing margins. Using a 15-drug GBM-targeted panel, ERK (ulixertinib) and PI3K pathway (paxalisib, CC-115) inhibitors showed preferential efficacy in enhancing cores and non-enhancing margins, respectively. The anti-apoptosis, pan-Bcl2 agent navitoclax and the epigenetic drug trotabresib represented the most effective, tumor-wide monotherapies. Importantly, drug combinations generally outperformed single agents across all regions. Conclusions: This work demonstrates the regional heterogeneity of therapeutic vulnerabilities in GBM ex vivo, showing various drugs with tumor-wide or MRI-enhancement informed activity. These findings offer preclinical bases of numerous monotherapies and drug combinations for future clinical trial design.
- 1 June 2025
- Published by Wolters Kluwer Health in Continuum
- Vol. 31 (3) , 840-849
Management of Normal Pressure Hydrocephalus
OBJECTIVE: This article reviews the preoperative considerations, postoperative complications, and ongoing management of shunts for normal pressure hydrocephalus. LATEST DEVELOPMENTS: The radiographic pattern of disproportionately enlarged subarachnoid space hydrocephalus (DESH) predicts a positive response to permanent CSF diversion. MRI-safe programmable shunt valves allow for fluid drainage adjustment based on patients’ symptoms and radiographic images. Endoscopic third ventriculostomy is a viable alternative to shunting for patients with normal pressure hydrocephalus due to aqueductal stenosis. ESSENTIAL POINTS: Approximately 75% of patients with normal pressure hydrocephalus improve after shunt surgery regardless of shunt type or location. Clinical benefit and complication rates are similar for frontal and parietal ventricular catheter approaches. Acetazolamide is not an effective treatment for normal pressure hydrocephalus.
- 1 June 2025
- Published by Wolters Kluwer Health in Continuum
- Vol. 31 (3) , 840-849
Management of Normal Pressure Hydrocephalus
OBJECTIVE: This article reviews the preoperative considerations, postoperative complications, and ongoing management of shunts for normal pressure hydrocephalus. LATEST DEVELOPMENTS: The radiographic pattern of disproportionately enlarged subarachnoid space hydrocephalus (DESH) predicts a positive response to permanent CSF diversion. MRI-safe programmable shunt valves allow for fluid drainage adjustment based on patients’ symptoms and radiographic images. Endoscopic third ventriculostomy is a viable alternative to shunting for patients with normal pressure hydrocephalus due to aqueductal stenosis. ESSENTIAL POINTS: Approximately 75% of patients with normal pressure hydrocephalus improve after shunt surgery regardless of shunt type or location. Clinical benefit and complication rates are similar for frontal and parietal ventricular catheter approaches. Acetazolamide is not an effective treatment for normal pressure hydrocephalus.
- 13 May 2025
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 174 (2) , 381-389
Predictors of return to work following surgery in patients with glioblastoma: a retrospective multicenter study
Purpose While clinical outcomes of glioblastoma (GBM) are well-documented, its socio-economic impact, particularly on return to work (RTW) remains unexplored. In this study we aimed to identify the predictors of RTW at 6 months postoperatively in patients undergoing GBM treatment and to assess its association with post-operative neurological deficits and median overall survival (mOS). Methods We retrospectively studied 106 adults with pre-operative employment, undergoing primary GBM resection or biopsy at three tertiary centers. RTW at 3 and 6 months postoperatively were assessed using univariate and multivariate analyses. Results After 6 months 33 patients (33.1%) were able to RTW. Factors associated with lower odds of RTW included female sex (p = 0.039), Karnofsky Performance Scale (KPS) < 80 at 2 weeks (p = 0.034), and 3 months post-operatively (p = 0.0001), right handedness (p = 0.038), and subtotal resection (p = 0.042). On multivariate analysis female sex (OR 0.238, 95% CI 0.077–0.733, p = 0.012) and three-month postoperative KPS < 80 (OR 0.019, 95% CI 0.001–0.0293, p = 0.004) were the least likely to RTW at six months. Acute postoperative motor (p = 0.047), gait (p = 0.008) and cognitive deficits (p = 0.048) and persistent motor (p = 0.017), gait (p = 0.033) and language (p = 0.026) deficits were all associated with lesser RTW. Patients who returned to work had significantly longer mOS (21.44, p < 0.001). Conclusions RTW at 6 months post GBM Surgery corelates with improved mOS. Female sex and lower post-operative KPS scores were the strongest predictors of reduced RTW.
- 13 May 2025
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 174 (2) , 381-389
Predictors of return to work following surgery in patients with glioblastoma: a retrospective multicenter study
Purpose While clinical outcomes of glioblastoma (GBM) are well-documented, its socio-economic impact, particularly on return to work (RTW) remains unexplored. In this study we aimed to identify the predictors of RTW at 6 months postoperatively in patients undergoing GBM treatment and to assess its association with post-operative neurological deficits and median overall survival (mOS). Methods We retrospectively studied 106 adults with pre-operative employment, undergoing primary GBM resection or biopsy at three tertiary centers. RTW at 3 and 6 months postoperatively were assessed using univariate and multivariate analyses. Results After 6 months 33 patients (33.1%) were able to RTW. Factors associated with lower odds of RTW included female sex (p = 0.039), Karnofsky Performance Scale (KPS) < 80 at 2 weeks (p = 0.034), and 3 months post-operatively (p = 0.0001), right handedness (p = 0.038), and subtotal resection (p = 0.042). On multivariate analysis female sex (OR 0.238, 95% CI 0.077–0.733, p = 0.012) and three-month postoperative KPS < 80 (OR 0.019, 95% CI 0.001–0.0293, p = 0.004) were the least likely to RTW at six months. Acute postoperative motor (p = 0.047), gait (p = 0.008) and cognitive deficits (p = 0.048) and persistent motor (p = 0.017), gait (p = 0.033) and language (p = 0.026) deficits were all associated with lesser RTW. Patients who returned to work had significantly longer mOS (21.44, p < 0.001). Conclusions RTW at 6 months post GBM Surgery corelates with improved mOS. Female sex and lower post-operative KPS scores were the strongest predictors of reduced RTW.
- 30 December 2023
- Published by Springer Nature in Current Treatment Options in Oncology
- Vol. 24 (12) , 1962-1977
Systemic Therapy for Melanoma Brain and Leptomeningeal Metastases
Opinion statement Melanoma has a high propensity to metastasize to the brain which portends a poorer prognosis. With advanced radiation techniques and targeted therapies, outcomes however are improving. Melanoma brain metastases are best managed in a multi-disciplinary approach, including medical oncologists, neuro-oncologists, radiation oncologists, and neurosurgeons. The sequence of therapies is dependent on the number and size of brain metastases, status of systemic disease control, prior therapies, performance status, and neurological symptoms. The goal of treatment is to minimize neurologic morbidity and prolong both progression free and overall survival while maximizing quality of life. Surgery should be considered for solitary metastases, or large and/or symptomatic metastases with edema. Stereotactic radiosurgery offers a benefit over whole-brain radiation attributed to the relative radioresistance of melanoma and reduction in neurotoxicity. Thus far, data supports a more durable response with systemic therapy using combination immunotherapy of ipilimumab and nivolumab, though targeting the presence of BRAF mutations can also be utilized. BRAF inhibitor therapy is often used after immunotherapy failure, unless a more rapid initial response is needed and then can be done prior to initiating immunotherapy. Further trials are needed, particularly for leptomeningeal metastases which currently require the multi-disciplinary approach to determine best treatment plan.
- 30 December 2023
- Published by Springer Nature in Current Treatment Options in Oncology
- Vol. 24 (12) , 1962-1977
Systemic Therapy for Melanoma Brain and Leptomeningeal Metastases
Opinion statement Melanoma has a high propensity to metastasize to the brain which portends a poorer prognosis. With advanced radiation techniques and targeted therapies, outcomes however are improving. Melanoma brain metastases are best managed in a multi-disciplinary approach, including medical oncologists, neuro-oncologists, radiation oncologists, and neurosurgeons. The sequence of therapies is dependent on the number and size of brain metastases, status of systemic disease control, prior therapies, performance status, and neurological symptoms. The goal of treatment is to minimize neurologic morbidity and prolong both progression free and overall survival while maximizing quality of life. Surgery should be considered for solitary metastases, or large and/or symptomatic metastases with edema. Stereotactic radiosurgery offers a benefit over whole-brain radiation attributed to the relative radioresistance of melanoma and reduction in neurotoxicity. Thus far, data supports a more durable response with systemic therapy using combination immunotherapy of ipilimumab and nivolumab, though targeting the presence of BRAF mutations can also be utilized. BRAF inhibitor therapy is often used after immunotherapy failure, unless a more rapid initial response is needed and then can be done prior to initiating immunotherapy. Further trials are needed, particularly for leptomeningeal metastases which currently require the multi-disciplinary approach to determine best treatment plan.
- 1 November 2023
- Published by Radiological Society of North America (RSNA) in Radiology: Imaging Cancer
- Vol. 5 (6) , e230078
Current State of Functional MRI in the Presurgical Planning of Brain Tumors
Surgical resection of brain tumors is challenging because of the delicate balance between maximizing tumor removal and preserving vital brain functions. Functional MRI (fMRI) offers noninvasive preoperative mapping of widely distributed brain areas and is increasingly used in presurgical functional mapping. However, its impact on survival and functional outcomes is still not well-supported by evidence. Task-based fMRI (tb-fMRI) maps blood oxygen level-dependent (BOLD) signal changes during specific tasks, while resting-state fMRI (rs-fMRI) examines spontaneous brain activity. rs-fMRI may be useful for patients who cannot perform tasks, but its reliability is affected by tumor-induced changes, challenges in data processing, and noise. Validation studies comparing fMRI with direct cortical stimulation (DCS) show variable concordance, particularly for cognitive functions such as language; however, concordance for tb-fMRI is generally greater than that for rs-fMRI. Preoperative fMRI, in combination with MRI tractography and intraoperative DCS, may result in improved survival and extent of resection and reduced functional deficits. fMRI has the potential to guide surgical planning and help identify targets for intraoperative mapping, but there is currently limited prospective evidence of its impact on patient outcomes. This review describes the current state of fMRI for preoperative assessment in patients undergoing brain tumor resection. Keywords: MR-Functional Imaging, CNS, Brain/Brain Stem, Anatomy, Oncology, Functional MRI, Functional Anatomy, Task-based, Resting State, Surgical Planning, Brain Tumor © RSNA, 2023.
- 1 November 2023
- Published by Radiological Society of North America (RSNA) in Radiology: Imaging Cancer
- Vol. 5 (6) , e230078
Current State of Functional MRI in the Presurgical Planning of Brain Tumors
Surgical resection of brain tumors is challenging because of the delicate balance between maximizing tumor removal and preserving vital brain functions. Functional MRI (fMRI) offers noninvasive preoperative mapping of widely distributed brain areas and is increasingly used in presurgical functional mapping. However, its impact on survival and functional outcomes is still not well-supported by evidence. Task-based fMRI (tb-fMRI) maps blood oxygen level-dependent (BOLD) signal changes during specific tasks, while resting-state fMRI (rs-fMRI) examines spontaneous brain activity. rs-fMRI may be useful for patients who cannot perform tasks, but its reliability is affected by tumor-induced changes, challenges in data processing, and noise. Validation studies comparing fMRI with direct cortical stimulation (DCS) show variable concordance, particularly for cognitive functions such as language; however, concordance for tb-fMRI is generally greater than that for rs-fMRI. Preoperative fMRI, in combination with MRI tractography and intraoperative DCS, may result in improved survival and extent of resection and reduced functional deficits. fMRI has the potential to guide surgical planning and help identify targets for intraoperative mapping, but there is currently limited prospective evidence of its impact on patient outcomes. This review describes the current state of fMRI for preoperative assessment in patients undergoing brain tumor resection. Keywords: MR-Functional Imaging, CNS, Brain/Brain Stem, Anatomy, Oncology, Functional MRI, Functional Anatomy, Task-based, Resting State, Surgical Planning, Brain Tumor © RSNA, 2023.
- Open Access
- 13 October 2023
- Published by Wolters Kluwer Health in Neurosurgery Practice
- Vol. 4 (4)
Phase 1, Dose Escalation, Nonrandomized, Open-Label, Clinical Trial Evaluating the Safety and Preliminary Efficacy of Allogenic Adipose-Derived Mesenchymal Stem Cells for Recurrent Glioblastoma: A Clinical Trial Protocol
BACKGROUND AND OBJECTIVES: Despite standard of care with maximal safe resection and chemoradiation, glioblastoma (GBM) is the most common and aggressive type of primary brain cancer. Surgical resection provides a window of opportunity to locally treat gliomas while the patient is recovering and before initiating concomitant chemoradiation. The objective was to assess the safety and establish the maximum tolerated dose of adipose-derived mesenchymal stem cells (AMSCs) for the treatment of recurrent GBM. Secondary objectives were to assess the toxicity profile and long-term survival outcomes of patients enrolled in the trial. In addition, biospecimens will be collected to explore the local and systemic responses to this therapy. METHODS: We will conduct a phase 1, dose-escalated, nonrandomized, open-label, clinical trial of patients with GBM who are undergoing surgical resection for recurrence. Up to 18 patients will receive intracavitary application of AMSCs encapsulated in fibrin glue during surgical resection. All patients will be followed for up to 5 years for safety and survival data. Adverse events will be recorded using the CTCAE V5.0. EXPECTED OUTCOMES: This study will explore the maximum tolerated dose of AMSCs along with the toxicity profile of this therapy in patients with recurrent GBM. In addition, preliminary long-term survival and progression-free survival outcome analysis will be used to power further randomized studies. Finally, cerebrospinal fluid and blood will be obtained throughout the treatment period to investigate circulating molecular and inflammatory tumoral/stem cell markers and explore the mechanism of action of the therapeutic intervention. DISCUSSION: This prospective translational study will determine the initial safety and toxicity profile of local delivery of AMSCs for recurrent GBM. It will also provide additional survival metrics for future randomized trials.
- 13 October 2023
- Published by Wolters Kluwer Health in Neurosurgery Practice
- Vol. 4 (4)
Open AccessPhase 1, Dose Escalation, Nonrandomized, Open-Label, Clinical Trial Evaluating the Safety and Preliminary Efficacy of Allogenic Adipose-Derived Mesenchymal Stem Cells for Recurrent Glioblastoma: A Clinical Trial Protocol
BACKGROUND AND OBJECTIVES: Despite standard of care with maximal safe resection and chemoradiation, glioblastoma (GBM) is the most common and aggressive type of primary brain cancer. Surgical resection provides a window of opportunity to locally treat gliomas while the patient is recovering and before initiating concomitant chemoradiation. The objective was to assess the safety and establish the maximum tolerated dose of adipose-derived mesenchymal stem cells (AMSCs) for the treatment of recurrent GBM. Secondary objectives were to assess the toxicity profile and long-term survival outcomes of patients enrolled in the trial. In addition, biospecimens will be collected to explore the local and systemic responses to this therapy. METHODS: We will conduct a phase 1, dose-escalated, nonrandomized, open-label, clinical trial of patients with GBM who are undergoing surgical resection for recurrence. Up to 18 patients will receive intracavitary application of AMSCs encapsulated in fibrin glue during surgical resection. All patients will be followed for up to 5 years for safety and survival data. Adverse events will be recorded using the CTCAE V5.0. EXPECTED OUTCOMES: This study will explore the maximum tolerated dose of AMSCs along with the toxicity profile of this therapy in patients with recurrent GBM. In addition, preliminary long-term survival and progression-free survival outcome analysis will be used to power further randomized studies. Finally, cerebrospinal fluid and blood will be obtained throughout the treatment period to investigate circulating molecular and inflammatory tumoral/stem cell markers and explore the mechanism of action of the therapeutic intervention. DISCUSSION: This prospective translational study will determine the initial safety and toxicity profile of local delivery of AMSCs for recurrent GBM. It will also provide additional survival metrics for future randomized trials.
- 25 September 2023
- Published by Wolters Kluwer Health in Operative Neurosurgery
- Vol. 26 (2) , 232
Endoscopic Endonasal Anterior Cranial Fossa Approach for Rare Giant Olfactory Schwannoma Resection: 2-Dimensional Operative Video
- 25 September 2023
- Published by Wolters Kluwer Health in Operative Neurosurgery
- Vol. 26 (2) , 232
Endoscopic Endonasal Anterior Cranial Fossa Approach for Rare Giant Olfactory Schwannoma Resection: 2-Dimensional Operative Video
- Open Access
- 23 May 2023
- Published by MDPI AG in Brain Sciences
- Vol. 13 (6) , 842
Current Role of Endoscopic Endonasal Approach for Craniopharyngiomas: A 10-Year Systematic Review and Meta-Analysis Comparison with the Open Transcranial Approach
In recent years, the endoscopic endonasal approach (EEA) for craniopharyngiomas has proven to be a safe option for extensive tumor resection, with minimal or no manipulation of the optic nerves and excellent visualization of the superior hypophyseal branches when compared to the Transcranial Approach (TCA). However, there is an ongoing debate regarding the criteria for selecting different approaches. To explore the current results of EEA and discuss its role in the management of craniopharyngiomas, we performed MEDLINE, Embase, and LILACS searches from 2012 to 2022. Baseline characteristics, the extent of resection, and clinical outcomes were evaluated. Statistical analysis was performed through an X2 and Fisher exact test, and a comparison between quantitative variables through a Kruskal–Wallis and verified with post hoc Bonferroni. The tumor volume was similar in both groups (EEA 11.92 cm3, -TCA 13.23 cm3). The mean follow-up in months was 39.9 for EEA and 43.94 for TCA, p = 0.76). The EEA group presented a higher visual improvement rate (41.96% vs. 25% for TCA, p < 0.0001, OR 7.7). Permanent DI was less frequent with EEA (29.20% vs. 67.40% for TCA, p < 0.0001, OR 0.2). CSF Leaks occurred more frequently with EEA (9.94% vs. 0.70% for TCA, p < 0.0001, OR 15.8). Recurrence rates were lower in the EEA group (EEA 15.50% vs. for TCA 21.20%, p = 0.04, OR 0.7). Our results demonstrate that, in selected cases, EEA for resection of craniopharyngiomas is associated with better results regarding visual preservation and extent of tumor resection. Postoperative CSF leak rates associated with EEA have improved compared to the historical series. The decision-making process should consider each person’s characteristics; however, it is noticeable that recent data regarding EEA justify its widespread application as a first-line approach in centers of excellence for skull base surgery.
- 23 May 2023
- Published by MDPI AG in Brain Sciences
- Vol. 13 (6) , 842
Open AccessCurrent Role of Endoscopic Endonasal Approach for Craniopharyngiomas: A 10-Year Systematic Review and Meta-Analysis Comparison with the Open Transcranial Approach
In recent years, the endoscopic endonasal approach (EEA) for craniopharyngiomas has proven to be a safe option for extensive tumor resection, with minimal or no manipulation of the optic nerves and excellent visualization of the superior hypophyseal branches when compared to the Transcranial Approach (TCA). However, there is an ongoing debate regarding the criteria for selecting different approaches. To explore the current results of EEA and discuss its role in the management of craniopharyngiomas, we performed MEDLINE, Embase, and LILACS searches from 2012 to 2022. Baseline characteristics, the extent of resection, and clinical outcomes were evaluated. Statistical analysis was performed through an X2 and Fisher exact test, and a comparison between quantitative variables through a Kruskal–Wallis and verified with post hoc Bonferroni. The tumor volume was similar in both groups (EEA 11.92 cm3, -TCA 13.23 cm3). The mean follow-up in months was 39.9 for EEA and 43.94 for TCA, p = 0.76). The EEA group presented a higher visual improvement rate (41.96% vs. 25% for TCA, p < 0.0001, OR 7.7). Permanent DI was less frequent with EEA (29.20% vs. 67.40% for TCA, p < 0.0001, OR 0.2). CSF Leaks occurred more frequently with EEA (9.94% vs. 0.70% for TCA, p < 0.0001, OR 15.8). Recurrence rates were lower in the EEA group (EEA 15.50% vs. for TCA 21.20%, p = 0.04, OR 0.7). Our results demonstrate that, in selected cases, EEA for resection of craniopharyngiomas is associated with better results regarding visual preservation and extent of tumor resection. Postoperative CSF leak rates associated with EEA have improved compared to the historical series. The decision-making process should consider each person’s characteristics; however, it is noticeable that recent data regarding EEA justify its widespread application as a first-line approach in centers of excellence for skull base surgery.
- 18 April 2023
- Published by Elsevier in Neurosurgery Clinics of North America
- Vol. 34 (3) , 403-415
Management of Intraventricular Meningiomas
- 18 April 2023
- Published by Elsevier in Neurosurgery Clinics of North America
- Vol. 34 (3) , 403-415
Management of Intraventricular Meningiomas
- 28 March 2023
- Published by Springer Nature in Acta Neurochirurgica
- Vol. 165 (5) , 1333-1343
Predictive factors for post operative seizures following meningioma resection in patients without preoperative seizures: a multicenter retrospective analysis
Purpose Meningiomas are the most common primary brain tumor and represent 35% of all intracranial neoplasms. However, in the early post-operative period approximate 3–5% of patients experience an acute symptomatic seizure. Establishing risk factors for postoperative seizures will identify those patients without preoperative seizures at greatest risk of postoperative seizures and may guide antiseizure medications (ASMs) management. Methods Adult seizure naïve patients who underwent primary resection of a World Health Organization (WHO) Grade 1–3 meningioma at the three Mayo Clinic Campuses between 2012–2022 were retrospectively reviewed. Multivariate regression analyses were used to identify radiological, surgical, and management features with the development of new-onset seizures in patients undergoing meningioma resection. Results Of 113 seizure naïve patients undergoing meningioma resection 11 (9.7%) experienced a new-onset post-operative seizure. Tumor volume ≥ 25 cm3 (Odds Ratio (OR) 5.223, 95% Confidence Interval (CI) 1.546 – 17.650, p = 0.008) and cerebral convexity meningiomas (OR 4.742, 95% CI 1.255 – 14.336, p = 0.016) were most associated with new onset postoperative seizures in multivariate analysis. ASMs and corticosteroid therapies did not display a significant difference among those with and without a new onset postoperative seizure. Conclusion In the current study, a larger tumor volume (≥ 25 cm3) and/or convexity meningiomas predicted the development of new onset post-operative seizures. Those who present with these factors should be counseled for their increased risk of new onset post-operative seizures and may benefit from prophylactic ASMs therapy.
- 28 March 2023
- Published by Springer Nature in Acta Neurochirurgica
- Vol. 165 (5) , 1333-1343
Predictive factors for post operative seizures following meningioma resection in patients without preoperative seizures: a multicenter retrospective analysis
Purpose Meningiomas are the most common primary brain tumor and represent 35% of all intracranial neoplasms. However, in the early post-operative period approximate 3–5% of patients experience an acute symptomatic seizure. Establishing risk factors for postoperative seizures will identify those patients without preoperative seizures at greatest risk of postoperative seizures and may guide antiseizure medications (ASMs) management. Methods Adult seizure naïve patients who underwent primary resection of a World Health Organization (WHO) Grade 1–3 meningioma at the three Mayo Clinic Campuses between 2012–2022 were retrospectively reviewed. Multivariate regression analyses were used to identify radiological, surgical, and management features with the development of new-onset seizures in patients undergoing meningioma resection. Results Of 113 seizure naïve patients undergoing meningioma resection 11 (9.7%) experienced a new-onset post-operative seizure. Tumor volume ≥ 25 cm3 (Odds Ratio (OR) 5.223, 95% Confidence Interval (CI) 1.546 – 17.650, p = 0.008) and cerebral convexity meningiomas (OR 4.742, 95% CI 1.255 – 14.336, p = 0.016) were most associated with new onset postoperative seizures in multivariate analysis. ASMs and corticosteroid therapies did not display a significant difference among those with and without a new onset postoperative seizure. Conclusion In the current study, a larger tumor volume (≥ 25 cm3) and/or convexity meningiomas predicted the development of new onset post-operative seizures. Those who present with these factors should be counseled for their increased risk of new onset post-operative seizures and may benefit from prophylactic ASMs therapy.